PhD student CIT-3 department, Roche Innovation Center Zürich

At Roche, we believe it's urgent to deliver medical solutions right now - even as we develop innovations for the future. We are passionate about transforming patients' lives and we are fearless in both decision and action. And we believe that good business means a better world.

That is why we come to work each day. We commit ourselves to scientific rigour, unassailable ethics, and access to medical innovations for all. We do this today to build a better tomorrow.

Targeting tumor-infiltrating Tregs-likely as part of a multi-modal treatment strategy including CPI and radio/ chemotherapy-offers an exciting treatment paradigm to re-establish anti-tumor immunity and break immunosuppressive networks within the tumor microenvironment. RG6292, an afucosylated human IgG1 antibody currently in Phase1 clinical trials (WP41188), depletes selectively CD25++ Treg cells whilst allowing intratumoral cytotoxic T cells to thrive unhindered on IL-2.

We are looking for a highly motivated scientist to join as PhD student the CIT-3 Department at Roche Innovation Center Zürich (Schlieren, Switzerland). You will work in close collaboration with in vivo pharmacology, toxicology, modelling & simulation as well as global renowned oncology experts to establish an understanding of the interplay of CPI with RG6292 mediated Treg depletion and optimize the treatment regimen accordingly.

The Roche Innovation Center Zurich (Schlieren, Switzerland) is active in the research and development of engineered therapeutic antibodies, with a focus on the fields of cancer immunotherapy and immunotherapy in general. Part of the Roche Group since 2005, it employs about 130 people.

We are keen to discover talents who are passionate about learning and show great curiosity in discovering new things. We contribute our share towards achieving our mission and to make our vision of personalized healthcare happen. We offer you a multicultural workplace in a modern environment, which at the same time requires you to be open-minded and adaptable. You provide us with examples that prove your ability to cultivate collaborations with different partners. This also means that you continuously compare your results with others and acknowledge the benefit of collaboration and communications.

Who you are

You have a masters degree Master's degree with recent research experience in cell biology, tumor immunology or similar area or a related field. You are motivated to increase and share your theoretical and practical knowledge on this emerging and exciting field of cancer immunotherapy. You are flexible, proactive, curious and an enthusiast of new technologies and you easily show engagement with people.

Further qualifications:

• Good written and verbal English is mandatory

• Strong communication and presentation skills

• Ability to work effectively and independently within a diverse group of people

• Excellent organizational skills, ability to take initiative and work according to time-lines

• A plus is hands-on experience with mouse in vivo studies, mammalian cell culture, PBMC isolation and handling.

• A plus is hands-on experience with tumor cell-immune cell co-cultures, various cell biology techniques and state-of-the art immunoprofiling techniques for functional characterization of immune cell responses (multiparametric analysis by flow cytometry, MACS sorting, ELISA, luminescence)

If you still have questions then please check our FAQs and videos on careers.roche.ch/faq.

If you are proud of contributing and feel you have the dedication to teamwork and innovation that we are seeking, then Roche is the organization for you. Every role at Roche plays a part in making a difference to patients' lives. If you want work in a passionate team, make your mark & improve lives, apply now.

The preferred start date of the PhD study is July 2020 or upon availability. Please clearly indicate your preferred starting date a on your motivation letter. Applications need to include a CV and a motivation letter both merged in one document.

Roche embraces diversity and equal opportunity in a serious way. We are committed to building a team that represents a variety of backgrounds, perspectives, and skills. The more inclusive we are, the better our work will be.